Hosted on MSN
SLS vs. TERN: Which pharma stock has more upside as Merck eyes $6B cancer bet ahead of Keytruda patent cliff
・SLS and TERN are advancing leukemia therapies, with TERN-701 targeting CML and GPS positioned as a Phase 3 maintenance immunotherapy in AML. ・Sellas is approaching a Phase 3 Regal survival readout, a ...
A genetic alteration that is already routinely analyzed in patients with acute myeloid leukemia can be used to identify patients who respond to a new targeted therapy, according to a study published ...
At the European Hematology Association (EHA) 2025 Congress, Ashley Yocum, PhD, highlights how the Beat AML Master Trial advances safe, personalized treatment and expands targeted therapy options for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results